Frequent mutations on other epigenetic modifiers in CTC- and primary-specific mutations were not identical in that CTC-specific mutations were observed on ASXL1 and TET1 while primary-specific mutations were common in KMT2D, KDM6A, and ARID1A. Pathway-level convergent mutations targeting different context of epigenetic regulators highlight the importance of epigenetic dysregulation in the pathogenesis of bladder cancers. This evidence concerns the gene TET1 and urinary bladder cancer.